2 results
Approved WMOCompleted
The primary objective of this study is to assess the objective response rates (ORR) for two starting doses of vandetanib, 150 mg and 300 mg in patients with unresectable locally advanced or metastatic MTC having progressive or symptomatic disease.…
Approved WMOCompleted
Primary: To compare immunogenicity (humoral and cellular) induced by PCV10 and PCV13 after the booster dose of a complete vaccination series (3+1, the current NIP schedule) Secondary: To compare immunogenicity (humoral) induced by PCV10 and PCV13 at…